Radiomics in esophageal and gastric cancer

Abdom Radiol (NY). 2019 Jun;44(6):2048-2058. doi: 10.1007/s00261-018-1724-8.

Abstract

Esophageal, esophago-gastric, and gastric cancers are major causes of cancer morbidity and cancer death. For patients with potentially resectable disease, multi-modality treatment is recommended as it provides the best chance of survival. However, quality of life may be adversely affected by therapy, and with a wide variation in outcome despite multi-modality therapy, there is a clear need to improve patient stratification. Radiomic approaches provide an opportunity to improve tumor phenotyping. In this review we assess the evidence to date and discuss how these approaches could improve outcome in esophageal, esophago-gastric, and gastric cancer.

Keywords: Computed tomography; Esophageal cancer; Esophagogastric junction cancer; Magnetic resonance imaging; Positron emission tomography; Radiomics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Combined Modality Therapy
  • Contrast Media
  • Esophageal Neoplasms / diagnostic imaging*
  • Esophageal Neoplasms / mortality
  • Esophageal Neoplasms / pathology
  • Esophageal Neoplasms / therapy*
  • Esophagogastric Junction / pathology
  • Humans
  • Neoplasm Staging
  • Phenotype
  • Quality of Life
  • Radiopharmaceuticals
  • Stomach Neoplasms / diagnostic imaging*
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / therapy
  • Survival Rate

Substances

  • Contrast Media
  • Radiopharmaceuticals